Hemab Therapeutics Holdings Inc., a clinical-stage biotechnology company, is seeking to raise as much as $212 million in a US initial public offering.

Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals ...

This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen ...

Alex Karnal, co-founder and CIO of Braidwell, a life sciences investment firm, spent 20 years building and backing biotech ...

On February 16, Franklin Equity said the biotechnology industry has entered 2026 on a firmer footing following an extended ...

This business acquisition appears to be a genetic match: Colossal Biosciences, the company that brought back the dire wolves, has acquired Viagen Pets and Equine, which has cloned dogs for Paris ...

Century Therapeutics (IPSC) analysis: autoimmune CAR-cell pivot, CNTY-813 Type 1 diabetes upside, cash burn cuts, rNPV fair ...

A Woburn biotechnology company laid off more than 200 Massachusetts employees last week, and state filings warn more cuts may ...

(NASDAQ:KYMR) is among the best biotech stocks. TheFly reported on April 13 that KYMR announced that the U.S. Food and Drug ...

4P004 is a GLP-1 analog specifically engineered for intra-articular administration in the knee. It is designed to leverage the pleiotropic properties of GLP-1, including analgesic, anti-inflammatory, ...

The full picture of Replimune's layoffs is coming into focus — and more employees are on the chopping block than previously ...